In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists,
Bayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new drugs for cardiovascular and gynaecological diseases and cancer, as well a
